- Home
- FHTX vs PMM Comparison
FHTX vs PMM Comparison
Compare FHTX & PMM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FHTX
- PMM
- Stock Information
- Founded
- FHTX 2015
- PMM 1989
- Country
- FHTX United States
- PMM United States
- Employees
- FHTX N/A
- PMM N/A
- Industry
- FHTX Medicinal Chemicals and Botanical Products
- PMM Investment Managers
- Sector
- FHTX Health Care
- PMM Finance
- Exchange
- FHTX Nasdaq
- PMM Nasdaq
- Market Cap
- FHTX 278.1M
- PMM 260.9M
- IPO Year
- FHTX 2020
- PMM N/A
- Fundamental
- Price
- FHTX $4.23
- PMM $6.08
- Analyst Decision
- FHTX Strong Buy
- PMM
- Analyst Count
- FHTX 5
- PMM 0
- Target Price
- FHTX $11.80
- PMM N/A
- AVG Volume (30 Days)
- FHTX 270.7K
- PMM 118.3K
- Earning Date
- FHTX 10-31-2025
- PMM 01-01-0001
- Dividend Yield
- FHTX N/A
- PMM 4.68%
- EPS Growth
- FHTX N/A
- PMM N/A
- EPS
- FHTX N/A
- PMM 0.23
- Revenue
- FHTX $24,173,000.00
- PMM N/A
- Revenue This Year
- FHTX $42.43
- PMM N/A
- Revenue Next Year
- FHTX $14.77
- PMM N/A
- P/E Ratio
- FHTX N/A
- PMM $26.52
- Revenue Growth
- FHTX N/A
- PMM N/A
- 52 Week Low
- FHTX $2.95
- PMM $5.00
- 52 Week High
- FHTX $9.70
- PMM $6.42
- Technical
- Relative Strength Index (RSI)
- FHTX 45.28
- PMM 48.42
- Support Level
- FHTX $3.85
- PMM $6.07
- Resistance Level
- FHTX $4.69
- PMM $6.16
- Average True Range (ATR)
- FHTX 0.33
- PMM 0.04
- MACD
- FHTX 0.04
- PMM -0.01
- Stochastic Oscillator
- FHTX 55.77
- PMM 4.15
About FHTX Foghorn Therapeutics Inc.
Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.
About PMM Putnam Managed Municipal Income Trust
Putnam Managed Municipal Income Trust is a closed-end management investment company. Its investment objective is to seek a high level of current income exempt from federal income tax by investing in a diversified portfolio of tax-exempt municipal securities. The Fund invests in various sectors such as healthcare, retirement community, private higher education, housing-backed, essential service utilities, and state-backed bonds.